RARE vs STRO · rev $560.2M vs rev $62.0M
Ultragenyx (RARE) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
RARE currently screens at market cap $2.79B. STRO currently screens at market cap $470.8M.
Not investment advice. Open the RARE and STRO stock pages for the full models.
Not investment advice.